MedTrace Logo

Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET

NCT01699828 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2014-06-04

No results posted yet for this study

Summary

The objective of the present study is to use positron emission tomography brain imaging to investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin partial agonist but has recently been identified as a D3 antagonist. It is hypothesized that clinically relevant doses of buspirone will occupy the D3 receptor.

Conditions

  • Smoking Cessation
  • Tobacco Use Cessation

Interventions

DRUG

Buspirone

The buspirone will be given once as a tablet and encapsulated for blinding.

DRUG

Placebo

Placebo will be lactose and encapsulated for blinding. A single capsule will be given.

Sponsors & Collaborators

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Isabelle Boileau, PhD · Center for Addiction and Mental Health

  • Bernard Le Foll, MD, PhD · Center for Addiction and Mental Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01699828 on ClinicalTrials.gov